ABPO 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-08-14

• Our two lead product candidates, ABP-102 and ABP-201, feature our next generation tetravalent antibody format, or TetraBi antibody format, which binds to two different targets with two distinct binding sites per target. ABP-102 is designed to redirect a patient’s immune system to fight cancer by eng…

• Following the Nasdaq delisting of our securities from the Nasdaq Capital Market, effective February 23, 2026, our securities are trading on the OTC Pink Limited Market under the ticker symbol “ABPO”. The delisting does not affect the Company’s operations, but may have, among other material adverse e…

• On May 28, 2026, the Company received written notification from the Nasdaq Listing and Hearing Review Council (the “Council”) that the Council had reviewed the decision of the Nasdaq Hearings Panel (the “Panel”) of the Nasdaq Stock Market LLC (“Nasdaq”) and had determined to reaffirm the Panel’s dec…

• The Company expects that Nasdaq may file a Form 25 with the SEC to delist the securities from Nasdaq and deregister the securities under Section 12(b) of the Securities Exchange Act of 1934, as amended (potentially) in the coming days.

• The Company expects its common stock will continue to be eligible for quotation on the OTC Pink Limited Market under its existing symbol, “ABP” and its public warrants under the existing symbol “ABPWW.” The Company can provide no assurances that any broker-dealer will make a market in its common sto…

相对上期删除的文字 · 来源:10-Q · 2026-05-20

• Our two lead product candidates, ABP-102 and ABP-201, feature our next generation tetravalent antibody format, or TetraBi antibody format, which binds to two different targets with two distinct binding sites per target.

• On November 13, 2024 (the “Closing Date”), Abpro Corporation (“Legacy Abpro”) completed the merger with Atlantic Coastal Acquisition Corp. II (“ACAB”) (the “Merger”). At the Closing Date, ACAB changed its name to “Abpro Holdings, Inc.”

• Our business and operations may be negatively affected by worldwide economic conditions, which may continue to be impacted by global macroeconomic challenges such as changes in trade policies, including sanctions, treaties, tariffs, regulatory requirements, and other limitations on cross-border oper…

• On October 16, 2025, the Company filed with the Delaware Secretary of State a Certificate of Amendment to the Certificate of Incorporation of the Company (the “Certificate of Amendment”), which became effective on October 31, 2025, to effect a one-for-thirty (1:30) reverse stock split (the “Reverse …

• As a result of the Reverse Stock Split, every 30 shares of issued and outstanding Common Stock were automatically combined into one (1) issued and outstanding share of Common Stock, without any change in the par value per share. No fractional shares were issued as a result of the Reverse Stock Split…

相对上期新增的文字 · 来源:10-Q · 2026-08-14

• On August 5, 2026, the Company received a demand letter from counsel to a former officer, in connection with the termination of his employment in November 2025, claiming bonus, unpaid wages during the furlough period and contractual severance payments. The demand letter requested the total payment o…

相对上期新增的文字 · 来源:10-Q · 2026-08-14

• Our failure to meet Nasdaq’s continued listing requirements could result in a further delisting of our shares.

• In April 2025, the Company received multiple notices from the Listing Qualifications Department staff of the Nasdaq Stock Market (“Nasdaq”) indicating that it no longer met several continued listing requirements. Specifically, its stock price had remained below Nasdaq’s $1.00 minimum bid price requi…

• After failing to satisfy the minimum bid price requirement by the September 2025 deadline, the Company requested a hearing before a Nasdaq Hearings Panel (the “Panel”). At an October 2025 hearing, management presented its plan to regain compliance with the minimum bid price, MVPHS, and MVLS requirem…

• The Company did not meet the required equity standard by the deadline, and on February 18, 2026, the Panel notified the Company that its securities would be delisted. Trading of the Company’s stock on Nasdaq was suspended on February 23, 2026, and the shares began trading on the OTC Pink Limited Mar…

• The delisting does not affect the Company’s operations, but may have, among other material adverse effects, an adverse impact on the liquidity and market price of the Common Stock and on the Company’s ability to raise capital, including under the SEPA (see Note 10 of the Notes to the Unaudited Conde…